VaxInnate to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
July 01, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, July 1, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present a company overview at Cantor...
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
June 17, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study
June 03, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 3, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
Vaxin Names Elizabeth Adkins Czerepak as Chief Financial Officer
April 13, 2015 08:30 ET
|
Vaxin Inc.
GAITHERSBURG, MD--(Marketwired - Apr 13, 2015) - Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
April 07, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
Vaxin CEO to Present at Future Leaders in the Biotech Industry Conference
March 17, 2015 08:30 ET
|
Vaxin Inc.
GAITHERSBURG, MD--(Marketwired - Mar 17, 2015) - Vaxin, a clinical stage vaccine development company, today announced that CEO Bill Enright will present at the Future Leaders in the Biotech...
Vaxin Enters Definitive Agreement to Acquire Immune Targeting Systems (ITS); Secures $16M in New Financing
February 17, 2015 08:30 ET
|
Vaxin Inc.
GAITHERSBURG, MD--(Marketwired - Feb 17, 2015) - Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has...
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines
February 17, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced that it has
executed a contract modification...
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
December 08, 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints
November 11, 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering
next-generation vaccine technology, announced today that enrollment
has concluded in the Phase 1...